BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $17.97, for a total value of $53,910.00. Following the transaction, the vice president now owns 44,074 shares of the company’s stock, valued at approximately $792,009.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Todd Berard also recently made the following trade(s):
- On Monday, July 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The shares were sold at an average price of $16.58, for a total value of $49,740.00.
- On Monday, June 17th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.47, for a total value of $52,410.00.
BLFS traded up $0.42 on Monday, hitting $20.20. The company had a trading volume of 187,400 shares, compared to its average volume of 175,530. The company has a market cap of $396.72 million, a PE ratio of 144.29 and a beta of 1.37. BioLife Solutions Inc has a 12-month low of $9.15 and a 12-month high of $26.35. The company has a quick ratio of 12.99, a current ratio of 9.42 and a debt-to-equity ratio of 0.02. The business’s fifty day simple moving average is $17.80 and its 200 day simple moving average is $17.54.
BLFS has been the subject of several recent research reports. BidaskClub upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Zacks Investment Research lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Maxim Group set a $24.00 price target on BioLife Solutions and gave the stock a “buy” rating in a research report on Friday, August 9th. Northland Securities reiterated a “buy” rating and issued a $18.00 price target on shares of BioLife Solutions in a research report on Tuesday, July 9th. Finally, HC Wainwright initiated coverage on BioLife Solutions in a research report on Monday, July 22nd. They issued a “buy” rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $18.67.
A number of hedge funds and other institutional investors have recently made changes to their positions in BLFS. JPMorgan Chase & Co. bought a new stake in BioLife Solutions in the second quarter worth about $30,000. Cowen Prime Services LLC bought a new stake in BioLife Solutions in the first quarter worth about $63,000. Signaturefd LLC bought a new stake in BioLife Solutions in the first quarter worth about $161,000. Alpine Woods Capital Investors LLC bought a new stake in BioLife Solutions in the second quarter worth about $170,000. Finally, Morgan Stanley lifted its stake in BioLife Solutions by 17.5% in the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after purchasing an additional 1,713 shares during the last quarter. 47.86% of the stock is owned by institutional investors and hedge funds.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.